Hematologic Oncology

Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

The expert panel explores the approval of ruxolitinib for chronic GVHD based on the REACH3 trial. The panel highlights the trial’s outcomes, long-term follow-up data, and the evolving shift in clinical practices.

The panel examines the transition from systemic steroids to second-line therapies in chronic GVHD, explore standardized clinical trial definitions and real-world challenges in treating chronic GVHD.

An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML.

Minoo Battiwalla, MD, discusses findings from a study of outpatient care after CAR T-cell therapy in patients with hematologic malignancies.

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, share considerations for sequencing CAR T-cell therapies in patients with LBCL, depending on treatments they have already received.

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss the trajectory and role of of CAR T-cell therapy within the treatment spectrum for LBCL.

Gabriela Hobbs, MD, discusses the significance of key research across myeloproliferative neoplasms from the 2023 ASH Annual Meeting.

Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.

A panel of experts on myelodysplastic syndromes (MDS) introduce themselves and provide an overview of diagnosis practices, highlighting common symptoms and the typical patient presentation.

Teresa Caprice, PA-C, discusses the use of post-transplant cyclophosphamide to address disparities in transplant outcomes in racial and ethnic populations.

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.

Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

VDA-1102 led to an objective response rate of 56% in patients with mycosis fungoides, according to findings from an interim analysis of a phase 2a study.

Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.

Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.

Summarize ongoing and recently completed clinical trials related to allo-HSCT and associated therapies.

Dr. Bijal and colleagues discuss the objectives, clinical outcomes, and safety profile of the Phase 2 ZUMA 3 clinical trial, which evaluated treatment of adult patients with relapsed or refractory, B-precursor, acute lymphoblastic leukemia with the anti-CD-19/anti-CD20 bispecific CAR-T cell therapy, KTE-X19 (brexucabtagene autoleucel).

Drs. Roloff, Park, and Shah provide a brief overview of the current, CAR-T cell therapeutic landscape for relapsed or refractory acute lymphoblastic leukemia in adults with a particular focus on those who have completed two or more lines of prior therapy.